Back to News
Market Impact: 0.18
N-Zyme Biomedical Program Receives US$2.76 Million NIH Award to Advance Fosamprenavir for PPI-Refractory GERD
Source: Business Wire
Healthcare & BiotechPrivate Markets & Venture
N-Zyme Biomedical received a US$2.76 million NIH award to advance fosamprenavir as a potential treatment for proton-pump-inhibitor-refractory gastroesophageal reflux disease (GERD). The non-dilutive funding supports further development of the program but is unlikely to have broad market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
More News
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- The race is on to build the first fusion power plant — and Europe is looking to Japan for help
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Crusoe sells troubled Wyoming data center project to Google
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO
- A long-term Elon Musk backer is cashing out of Tesla — and cutting its SpaceX exposure